# DESCRIPTION

## STATEMENT REGARDING FEDERAL FUNDING

- disclose government funding

## FIELD

- introduce CXCR4 modulators

## BACKGROUND

- introduce CXCR4 and CXCL12
- describe CXCR4's physiological roles
- discuss approved CXCR4-targeting drug
- highlight need for new CXCR4-acting agents
- describe chemokine signaling
- discuss CXCR4's role in development and cancer
- highlight importance of CXCR4 inhibition
- summarize previous approaches to CXCR4 antagonist discovery

## SUMMARY

- introduce small molecule CXCR4 modulators
- define compound formula
- describe compound's binding to CXCR4
- specify compound's activity as CXCR4 modulator
- list specific compounds
- describe methods of treating subjects
- describe methods of modulating CXCR4 activity

## DEFINITIONS

- introduce definitions
- clarify scope of invention
- define technical terms
- specify singular and plural forms
- define "comprise"
- define "consisting of"
- define "consisting essentially of"
- explain IUPAC nomenclature
- define "subject"
- define "patient"
- define "subject at risk for a disease"
- define "effective amount"
- define "administration"
- define "co-administration"
- define "pharmaceutical composition"
- define "pharmaceutically acceptable"
- define "pharmaceutically acceptable carrier"
- define "pharmaceutically acceptable salt"
- provide examples of acids
- provide examples of bases
- provide examples of salts
- define "instructions for administering"
- define "alkyl"
- define "alkylene"
- define alkenyl
- specify embodiments of alkenyl
- define alkenylene
- specify embodiments of alkenylene
- define alkynyl
- specify embodiments of alkynyl
- define alkynylene
- specify embodiments of alkynylene
- define amine
- define amide
- define linear alkyl
- specify designations of linear alkyl
- define Cx-y
- define branched alkyl
- define carbocycle
- specify embodiments of carbocycle
- define cycloalkyl
- specify embodiments of cycloalkyl
- specify substituents of cycloalkyl
- define cycloalkenyl
- describe cycloalkenyl examples
- define heteroalkyl
- describe heteroalkyl examples
- define heteroalkylene
- describe heteroalkylene examples
- define substituted
- describe substituted examples
- define optionally substituted
- describe optionally substituted examples
- define haloalkyl
- describe haloalkyl examples
- define aromatic ring
- describe aromatic ring examples
- define heteroaryl
- describe heteroaryl examples
- define heterocycle
- describe heterocycle examples
- define non-aromatic heterocycle
- describe non-aromatic heterocycle examples
- define absent
- describe absent in reference to functional group
- describe absent in reference to substituent
- describe absent in reference to position
- provide additional definitions
- provide additional examples
- provide additional descriptions
- conclude definitions section

## DETAILED DESCRIPTION

- introduce CXCR4 modulators
- describe CXCR4 receptor role
- motivate small molecule agonists
- describe difficulties in finding small molecule agonists
- summarize mutagenesis and crystal structure studies
- describe hit identification methods
- report initial screen results
- identify agonist compounds
- demonstrate agonist effects
- describe dual in silico screening strategy
- report in vitro assay results
- describe compositions and methods for disease treatment
- introduce compound structure of Formula (1)
- define variables in Formula (1)
- describe optional substituents on rings
- list possible functional groups for substitution
- describe G, A, and substituent selection
- provide examples of substituent groups
- describe J and L ring systems
- list examples of J and L ring systems
- define carbocycle
- define non-aromatic carbocycle
- define cycloalkyl ring
- define non-aromatic heterocycle
- define aryl
- define heteroaryl
- define two-ring system
- define X substituents
- describe composition
- describe compound structure
- describe disease treatment
- describe pharmaceutical composition
- describe therapeutic agent
- describe dosage
- describe administration route
- describe formulation techniques
- describe oral administration
- describe parenteral administration
- describe pharmaceutical carriers
- describe active ingredients
- describe pharmaceutical preparations
- describe oral formulations
- describe dragee cores
- describe coatings
- describe pharmaceutical preparations for oral administration
- describe push-fit capsules
- describe soft capsules
- describe therapeutic compositions
- describe salt formation
- describe lyophilized powder
- describe therapeutically effective dose
- describe combination therapy
- describe kits for use in methods

### EXPERIMENTAL

- describe experimental methods

### Annotated Database Creation

- create annotated database

### EXAMPLE 2

- select CXCR4 antagonists
- build common-feature pharmacophore model
- screen annotated database

### EXAMPLE 3

- analyze CXCR4 crystal structures
- prepare protein for docking
- perform structure-based virtual screen
- select hits from virtual screen

### EXAMPLE 4

- dock known antagonists
- analyze docked poses
- dock GPCR-focused library
- select in silico hits
- evaluate hits for further analysis

### EXAMPLE 5

- describe calcium imaging assay
- test compounds for biological activity
- determine IC50 values
- identify agonist and antagonist compounds

### EXAMPLE 6

- examine ERK activation by agonist NUCC-390

### EXAMPLE 7

- introduce CXCR4 receptors
- describe receptor internalization
- motivate NUCC-390
- describe experimental design
- present results of SDF-1 treatment
- present results of NUCC-390 treatment
- compare results of SDF-1 and NUCC-390
- discuss constitutive activity of CXCR4
- discuss inverse agonist activity of AMD-3100 and NUCC-380
- introduce chemotaxis
- motivate SDF-1 and NUCC-390
- describe Boyden chamber assay
- present results of SDF-1 and NUCC-390
- introduce compound synthesis
- describe general synthesis procedure
- describe synthesis of intermediates
- describe synthesis of final compounds
- present characterization data
- describe synthesis of amides 5a and 5b
- describe synthesis of compounds 6a and 6b
- describe general procedure III for synthesis of compounds 7a-7d
- describe synthesis of compound 7a
- describe synthesis of compound 7b
- describe synthesis of compound 7c
- describe synthesis of compound 7d
- introduce preparation of intermediates and final compounds shown in scheme B
- describe synthesis of tert-butyl 3-(2-ethoxy-2-oxoacetyl)-4-oxopiperidine-1-car
- describe synthesis of 5-tert-butyl 3-ethyl 1-isopentyl-6,7-dihydro-1H
- describe MS analysis of compound 10
- describe 1H NMR analysis of compound 10
- provide MS data for compound 9
- provide MS data for compound 10
- provide 1H NMR data for compound 10
- synthesize compound 11
- synthesize compound 12
- describe general procedure IV
- synthesize compound 13
- describe general procedure V
- synthesize compound 14a
- synthesize compound 15
- synthesize compound 16
- describe modifications of methods
- describe variations of compositions
- claim scope of invention
- disclaim limitations of invention

